At least six U.S. states, including Georgia, have decided they will not fully sign on to a proposed $26 billion settlement with three drug distributors and Johnson & Johnson, which have been accused of fueling the nation’s opioid epidemic, according to the states’ attorneys general.
States had until Saturday to decide whether to support the $21 billion proposed settlement hwith McKesson Corp., AmerisourceBergen Corp. and Cardinal Health Inc. and a separate $5 billion agreement with J&J.
But in a sign that talks were continuing despite the passing of the deadline, Georgia – the most populous hold-out state – on Monday indicated it could wind up backing the agreement.
“We have not rejected the deal, but we have not joined because at the present time joining the national settlements does not guarantee the best outcome for Georgia and its counties, cities and citizens,” said an emailed statement from the office of the attorney general, Christopher Carr. “We remain active in representing Georgia throughout negotiations, and we’re going to continue to get input from Georgia stakeholders.”
The state will litigate its claims if needed, the statement said.
New Mexico, Oklahoma, Washington and West Virginia also declined to join the deals, their state attorneys general said. New Hampshire agreed to the settlement with distributors but not the J&J agreement.
The complex settlement formula envisions at least 44 states participating, but ultimately the companies get to decide whether a “critical mass” has joined and whether to finalize the deal.
The size of the settlement is based on the number of participating states. Those that decline to join will instead seek a larger recovery by continuing to fight the defendants in the courts. The companies have already paid hundreds of millions in verdicts and other settlements.
The deal, which was unveiled by 14 state attorneys general on July 21, aims to resolve more than 3,000 lawsuits accusing the distributors of ignoring red flags that pain pills were being diverted into communities for illicit uses and that J&J played down the risks of opioid addiction.
The money would go toward funding treatment and other services.
The companies deny wrongdoing, saying the drugs were approved by the U.S. Food and Drug Administration and that responsibility for ballooning painkiller sales lies with others, including doctors and regulators.
McKesson said the companies have until Sept. 4 to determine if there is sufficient support for the agreements and said that process is ongoing. Cardinal Health and AmerisourceBergen declined to comment and J&J did not immediately respond to a request for comment.
The support of two other states, Nevada and Alabama, also appeared to be in doubt, according to sources familiar with the situation.
Nevada’s attorney general declined to comment and the Alabama attorney general did not respond to a request for comment.
The participation of states is tied closely to that of their local governments, which brought the majority of the lawsuits. Cities and counties within participating states would have through Jan. 2 to sign on. Ultimately, $10.7 billion of the settlement money is tied to the extent to which localities participate.
North Carolina Attorney General Josh Stein, a lead negotiator, last month said he expected “well north” of 40 states to join.
(Reporting by Nate Raymond in Boston and Tom Hals in Wilmington, Delaware; Editing by Noeleen Walder and Karishma Singh)
Was this article valuable?
Here are more articles you may enjoy.